Home

Pharmacology

Read time: 2 min

Congress highlights

Inflammation and glutamate dysregulation: unravelling the aetiology of schizophrenia

Reduced glutamatergic signalling and immune dysregulation are two major aetiological hypotheses in...

Read time: 2 min

Congress highlights

What causes migraine and how can it be prevented?

"Calcitonin gene-related peptide (CGRP) plays a causative role in migraine", said...

Read time: 3 min

Satellite symposium

Evolution of treatment strategies in MDD

Over the past 60 years, treatment for patients with major depressive disorder (MDD) has undergone...

Read time: 2 min

Congress highlights

Unmet needs in the acute treatment of migraine

What are the acute treatment options for migraine if current medications are not effective, are...

Read time: 3 min

Satellite symposium

Promising data in depression associated with emotional blunting or trauma

Treatment for depression should be tailored to individuals’ history and presentation....

Read time: 2 min

Congress highlights

Partial dopamine agonists: wide spectrum of activity and indications

Dopamine partial agonists decrease transmission when there is excess of the neurotransmitter, but...

Read time: 2 min

Congress highlights

Real world study casts new light on potential of polypharmacy

The fact that a high number of patients with schizophrenia are treated with more than one...

Neurotoriun

Neurotorium is your new point of reference for educational content on psychiatry, neurology, and neuroscience.

Country selection

We are registering that you are located in Brazil - if that's correct then please continue to Progress in Mind Brazil

Not located in Brazil?
Go to a different regional HUB

Continue to Progress in Mind Continue to Progress in Mind Brazil Continue to Progress in Mind MENA Continue to Progress in Mind Spain Continue to Progress in Mind Italy Continue to Progress in Mind Greece Continue to Progress in Mind South East Asia Continue to Progress in Mind Middle East & Africa Continue to Progress in Mind United Kingdom Continue to Progress in Mind Sweden Continue to Progress in Mind Norge Continue to Progress in Mind Denmark Continue to Progress in Mind Japan RC Continue to Progress in Mind България Continue to Progress in Mind Israel Continue to Progress in Mind Sweden Continue to Progress in Mind Finland Continue to Progress in Mind Ukraine Continue to Progress in Mind Belgium & Luxembourg Continue to Progress in Mind Switzerland Continue to Progress in Mind Germany Continue to Progress in Mind Austria

You are leaving Progress in Mind

Continue to

Cancel

Progress in Mind Belux

Accept Cancel

Login as a registered health care professional

Please enter your email to continue

Register as a health care professional

Please enter your email to continue

Hello
Please confirm your email

We have just sent you an email, with a confirmation link.
Before you can gain full access - you need to confirm your email.

The information on this site is exclusively intended for health care professionals.

All the information included in the Website is related to diseases, investigations and existing or potential treatment options and, therefore, directed to health professionals . The technical information of the drugs is provided merely informative, being the responsibility of the professionals authorized to prescribe drugs and decide, in each concrete case, the most appropriate treatment to the needs of the patient.

Accept

Decline

Congress

Register for access to Progress in Mind in your country